Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain

Last updated: March 17, 2019
Sponsor: Daewon Pharmaceutical Co., Ltd.
Overall Status: Completed

Phase

3

Condition

Pain (Pediatric)

Pain

Treatment

N/A

Clinical Study ID

NCT03221907
DW1502-301
  • Ages > 19
  • All Genders

Study Summary

A multi-center, randomized, double-blind, parallel, active-controlled phase III clinical trial to evaluate the efficacy and safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in peripheral neuropathic pain

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • both male and female who are over 19-year-old

  • patient whose pain scale is 4~9

  • patient who has pain of mononeuropathy

Exclusion

Exclusion Criteria:

  • patient whose CCr is <60ml/min

  • patient who has other pain which is not from mononeuropathy

  • patient who is going to have an operation during this study

  • patient who has abnormal ECG

Study Design

Total Participants: 352
Study Start date:
April 11, 2016
Estimated Completion Date:
January 08, 2019

Connect with a study center

  • Seoul National University Hospital

    Seoul,
    Korea, Republic of

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.